<DOC>
	<DOCNO>NCT02287649</DOCNO>
	<brief_summary>Aims study : 1 ) To determine whether presence V158 allele Fc gammaRIIIA gene associate well outcome Immune Thrombocytopenia ( ITP ) adult especially high response-rate rituximab . 2 ) To analyze impact therapy especially rituximab B T cell autoreactive subset peripheral blood . Patients Methods : Inclusion criterion : age ≥ 18 year , primary ITP define accord recent consensual criterion ( Rodeghiero F et al . Blood 2009 ) , active ITP define ITP platelet count &lt; 50 x 109/L require treatment , informed consent . Main exclusion criterion : secondary ITP . Blood sample ( serum , plasma , DNA ) collect every patient time inclusion ( pre-treatment ) sequentially 3 , 6 12 month inclusion patient treat rituximab remission phase treatment immunological study . When marrow analysis indicate , marrow specimen also collect studied patient undergo splenectomy standard care , spleen specimen also collect . Fc gamma RIIIA V/F158 polymorphism assess mean allele-specific PCR . The sequential analysis anti-platelets ( anti-GpIIbIIIa ) antibody produce B cell perform mean flow cytometry ELISPOT analysis . T cell subset harvest presence GpIIbIIIa immunodominant peptide cytokine expression measure supernatant day 2 11 vitro use Luminex technology order characterize distinguish TH1 , TH2 , TH17 , TFH Tregs subset . The primary outcome overall response rate 1 year inclusion define platelet count &gt; 30 x 109/L least two-fold increase initial ( pre-treatment ) count . For patient treat rituximab standard care , base overall expect response-rate ( 40-50 % ) base preliminary data FcgammaRIIIA V/F158 distribution , inclusion 85 patient sufficient show association V158 allele response ( b risk 20 % 5 % ) . Responders non responder compare non parametrical test , multivariate analysis perform use logistic regression model . The immunological data B T cell subset ) obtain responder non responder compare time ( To , M3 , M6 M12 ) non parametrical match test .</brief_summary>
	<brief_title>Polymorphism Auto-reactive B T Cells Subsets Adult 's Immune Thrombocytopenia ( ITP )</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>Age ≥ 18 year Primary ITP define internation consensus terminology ( Rodeghiero et al . Blood 2009 ) regardless phase disease ( newlydiagnosed , persistent chronic ITP ) active ITP define platelet count &lt; 50 x 109/L time inclusion indication treatment Informed consent Secondary ITP</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Immune thrombocytopenia</keyword>
	<keyword>Fc gamma RIIIA V/F158 polymorphism</keyword>
	<keyword>Rituximab</keyword>
	<keyword>autoreactive B T cell</keyword>
	<keyword>ITP</keyword>
</DOC>